Evidence map›Paper›PMID 31906797›Full record

ArticlemAbs

Discovery and characterization of single-domain antibodies for polymeric Ig receptor-mediated mucosal delivery of biologics.

Bharathikumar Vellalore Maruthachalam, Adam Zwolak, Xiefan Lin-Schmidt, Edward Keough, Ninkka Tamot, Sathya Venkataramani, Brian Geist, Sanjaya Singh, Rajkumar Ganesan

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Polymeric immunoglobulin receptor (pIgR) in cancer.Journal of cancer research and clinical oncology · 2023
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Bharathikumar Vellalore MaruthachalamJanssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.
Adam ZwolakJanssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.ORCID 0000-0001-6861-9078
Xiefan Lin-SchmidtJanssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.
Edward KeoughJanssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.
Ninkka TamotJanssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.ORCID 0000-0002-5538-190X
Sathya VenkataramaniJanssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.
Brian GeistJanssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.
Sanjaya SinghJanssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.
Rajkumar GanesanJanssen BioTherapeutics, Janssen Research and Development, Spring House, PA, USA.ORCID 0000-0002-3431-9664
Janssen (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucosal immunity is dominated by secretory IgA and IgM, although these are less favorable compared to IgG molecules for therapeutic development. Polymeric IgA and IgM are actively transported across the epithelial barrier via engagement of the polymeric Ig receptor (pIgR), but IgG molecules lack a lumen-targeted active transport mechanism, resulting in poor biodistribution of IgG therapeutics in mucosal tissues. In this work, we describe the discovery and characterization of single-domain antibodies (VHH) that engage pIgR and undergo transepithelial transport across the mucosal epithelium. The anti-pIgR VHH panel displayed a broad range of biophysical characteristics, epitope diversity, IgA competition profiles and transcytosis activity in cell and human primary lung tissue models. Making use of this diverse VHH panel, we studied the relationship between biophysical and functional properties of anti-pIgR binders targeting different domains and epitopes of pIgR. These VHH molecules will serve as excellent tools for studying pIgR-mediated transport of biologics and for delivering multispecific IgG antibodies into mucosal lumen, where they can target and neutralize mucosal antigens.

Indexed as

Receptors, Polymeric ImmunoglobulinSingle-Domain AntibodiesAnimalsBiological ProductsDrug Delivery SystemsDrug DiscoveryHumansImmunoglobulin GMucous MembraneTranscytosisBiological ProductsImmunoglobulin GReceptors, Polymeric ImmunoglobulinSingle-Domain Antibodiesbiodistributiondimeric IgApolymeric immunoglobulin receptorsingle domain antibodyTargeted delivery

Identifiers

PMID31906797
PMCPMC6973331
OpenAlexW2999347501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.